A method for producing lead-212 of very high radiological purity from an aqueous solution comprising thorium-228 and daughters thereof. Manufacture of radiopharmaceuticals based on lead-212, which are useful in nuclear medicine and, in particular, in targeted alpha radiation therapy for the treatment of cancers.

A method and system are disclosed for isolating intact acellular particles using size exclusion and for obtaining size and concentration of such isolated particles. In one embodiment, the disclosure is directed to use of Particle Purification Liquid Chromatography (PPLC), a high-resolution chromatographic size-guided turbidimetry-enabled system for dye-free isolation, on-line characterization, and retrieval of intact acellular particles, including extracellular vesicles (EVs) and membraneless condensate particles (MCs) from various biofluids.

The disclosure relates to a gradient twin column recycling chromatography method that is used to separate a mixture containing closely eluting compounds. In one embodiment, a sample includes a primary organic compound and one or more impurities that closely elute with the primary organic compound. A gradient mobile phase is initially used to remove unwanted early eluting and late eluting impurities from the sample. After the gradient removal of some of the impurities is complete, the remaining mixture of the primary organic compound and the closely eluting impurities are separated using recycle chromatography methodology with an isocratic mobile phase.

The present invention comprises a method for the generation of .sup.227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said .sup.223Ra and .sup.227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting .sup.227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first .sup.227Th solution containing contaminant .sup.223Ra and .sup.227Ac; v) loading the first .sup.227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant .sup.223Ra and .sup.227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the .sup.227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second .sup.227Th solution. Purified thorium-227 of pharmaceutical purity and a pharmaceutical composition comprising the same are also provided.

The present invention provides a chromatographic separation process for recovering a polyunsaturated fatty acid (PUFA) product from a feed mixture, which process comprises passing the feed mixture through one or more chromatographic columns containing, as eluent, an aqueous organic solvent, wherein the temperature of at least one of the chromatographic columns through which the feed mixture is passed is greater than room temperature.

The present invention relates to a column chromatographic method of manufacturing non-carrier-added high-purity .sup.177Lu compounds for medicinal purposes. In the method in accordance with the invention a cation exchanger and a suitable chelating agent are used. With the method in accordance with the invention it is possible for the first time to provide non-carrier-added high-purity .sup.177Lu compounds in milligram amounts for pharmaceutical-medicinal purposes from .sup.176Yb compounds irradiated with thermal neutrons, the radionuclides .sup.177Lu and .sup.176Yb being present in an approximate mass ratio of 1:10.sup.2 to 1:10.sup.10 for purification.

The present invention relates to improved processes and systems for purification of biological molecules, where the processes can be performed in a continuous manner.

A chemical liquid manufacturing apparatus, including a first system and a second system, is provided. The first system includes at least one first filtration medium, selected from a first filter, a first ion exchange membrane and a first ion adsorption membrane, wherein the first system is configured to process a material of at least one time. The second system includes at least one second filtration medium, selected from a second filter, a second ion exchange membrane and a second ion adsorption membrane, wherein the second system is configured for recirculation and to process the material of at least two times.

The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.

Methods of purifying adenovirus that can be performed on a large scale. The methods purify adenovirus from an adenovirus-containing sample comprising or derived from a host cell population by clarifying the sample, wherein clarification comprises depth filtration followed by microfiltration; processing the clarified sample by anion exchange chromatography; and processing the anion exchange product by tangential flow filtration (TFF) to provide a TFF product.